Article

Alharbi, H. O., Hardyman, M. A., Cull, J. J., Markou, T., Cooper, S. T. E., Glennon, P. E., Fuller, S. J., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2022) Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice. Clinical Science, 136 (22). pp. 1661-1681. ISSN 0143-5221 doi: 10.1042/CS20220607

Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708, Meijles, D. N., Hardyman, M. A., Fuller, S. J., Chothani, S. P., Cull, J. J., Cooper, S. T. E., Alharbi, H. O., Vanezis, K., Felkin, L. E., Markou, T., Leonard, S. J., Shaw, S. W., Rackham, O. J. L., Cook, S. A., Glennon, P. E., Sheppard, M. N., Sembrat, J. C., Rojas, M., McTiernan, C. F., Barton, P. J. and Sugden, P. H. (2022) Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo. Biochemical Journal, 479 (3). pp. 401-424. ISSN 0264-6021 doi: 10.1042/BCJ20210615

Meijles, D. N., Cull, J. J., Cooper, S. T. E., Markou, T., Hardyman, M. A., Fuller, S. J., Alharbi, H. O., Haines, Z. H. R., Alcantara Alonso, V. ORCID: https://orcid.org/0000-0002-9782-2398, Glennon, P. E., Sheppard, M. N., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2021) The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension. Clinical Science, 135 (14). pp. 1631-1647. ISSN 0143-5221 doi: 10.1042/CS20210192

Meijles, D. N., Zoumpoulidou, G., Markou, T., Rostron, K. A., Patel, R., Lay, K., Handa, B. S., Wong, B., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2019) The cardiomyocyte "redox rheostat": Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death. Journal of molecular and cellular cardiology, 129. pp. 118-129. ISSN 1095-8584 doi: 10.1016/j.yjmcc.2019.02.006